Bionano Genomics, Inc. Common Stock (BNGO) is a publicly traded Healthcare sector company. As of May 21, 2026, BNGO trades at $1.23 with a market cap of $12.87M and a P/E ratio of -0.28. BNGO moved +5.13% today. Year to date, BNGO is -22.01%; over the trailing twelve months it is -67.11%. Its 52-week range spans $1.06 to $30.52. Analyst consensus is buy with an average price target of $5.00. Rallies surfaces BNGO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bionano Genomics narrows Q1 loss to $0.76 and records flow cell sales: Bionano Genomics posted a Q1 net loss of $0.76 per share, beating estimates by $0.05 and improving from a $1.15 loss a year earlier. The company also reported record flow cell sales, reflecting rising demand for its optical genome mapping consumables.
| Metric | Value |
|---|---|
| Price | $1.23 |
| Market Cap | $12.87M |
| P/E Ratio | -0.28 |
| EPS | $-4.37 |
| Dividend Yield | 0.00% |
| 52-Week High | $30.52 |
| 52-Week Low | $1.06 |
| Volume | 202 |
| Avg Volume | 0 |
| Revenue (TTM) | $28.74M |
| Net Income | $-31.60M |
| Gross Margin | 46.97% |
2 analysts cover BNGO: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.00.